Re US Patent Office

ReNeuron Group plc
24 January 2006


ReNeuron receives Notice of Allowance from US Patent Office for neural stem cell
                       transplantation patent application



Guildford, UK, 24 January 2006: ReNeuron Group plc (LSE: RENE.L) today announced
that it has received a Notice of Allowance from the US Patent and Trademark
Office concerning a key patent application for methods of transplantation of
neural stem cells.


The patent application (No. 09/760274) contains broad claims covering methods of
treatment of different types of brain damage by the transplantation of
conditionally immortal1 stem cells.  The application encompasses cell lines
produced by technology that makes those cells conditionally immortal, such as
those generated using ReNeuron's proprietary c-mycERTAM platform technology.
Equivalent patents to this US application have already granted in Europe and
other significant territories.


Dr John Sinden, Chief Scientific Officer of ReNeuron, said:


'This allowance is an important enhancement to ReNeuron's already broad
portfolio of proprietary and licensed patents covering neural and other stem
cell types for therapeutic and other uses.   As a result, the Company remains
well-placed to aggressively protect its stem cell products and technologies from
an intellectual property perspective as those products move towards the
realization of their commercial potential.'


1.  Conditionally immortal stem cells are those that, through modification, are
capable of dividing indefinitely in vitro to produce stem cell lines, but whose
division can be fully arrested by various means, such as removal of certain
constituents present in the cell culture media.


Enquiries:


ReNeuron
Michael Hunt, Chief Executive Officer                    Tel: [phone]
John Sinden, Chief Scientific Officer


Financial Dynamics
David Yates                                              Tel: [phone]
Sarah Macleod


Notes to Editors


ReNeuron is a leading, UK-based adult stem cell therapy business. The Company is
applying its novel stem cell platform technologies in the development of
ground-breaking stem cell therapies to serve significant and unmet or poorly-met
clinical needs.


ReNeuron has used its c-mycERTAM technology to generate genetically stable
neural stem cell lines. This technology platform has multi-national patent
protection and is fully regulated by means of a chemically-induced safety
switch. Cell growth can therefore be completely arrested prior to in vivo
implantation.


The Company's lead stem cell therapy, ReN001 for chronic stroke disability, is
in late pre-clinical development.  The Company plans to file for approval to
commence initial clinical trials in stroke later this year, with trials
commencing as soon as possible thereafter.


In addition to its ReN001 stroke programme, ReNeuron has programmes to develop
stem cell therapies to address Huntington's disease, Parkinson's disease, Type 1
diabetes and diseases of the retina.


ReNeuron has also leveraged its stem cell technologies into non-therapeutic
areas - its ReNcell range of cell lines for use in drug discovery applications
in the pharmaceutical industry.


The Company successfully completed its flotation on the London AIM market in
August 2005, raising £9.5million before expenses.  At flotation, the Company
also issued warrants which, if exercised, will raise a further £5.7m for the
Company by February 2007.  ReNeuron's shares are traded under the symbol RENE.L,
and its warrants are traded under the symbol RENW.L.


Further information on ReNeuron and its products can be found at
www.reneuron.com.


This announcement contains forward-looking statements with respect to the
financial condition, results of operations and business achievements/performance
of ReNeuron and certain of the plans and objectives of management of ReNeuron
with respect thereto. These statements may generally, but not always, be
identified by the use of words such as 'should', 'expects', 'estimates',
'believes' or similar expressions. This announcement also contains
forward-looking statements attributed to certain third parties relating to their
estimates regarding the growth of markets and demand for products. By their
nature, forward-looking statements involve risk and uncertainty because they
reflect ReNeuron's current expectations and assumptions as to future events and
circumstances that may not prove accurate.  A number of factors could cause
ReNeuron's actual financial condition, results of operations and business
achievements/performance to differ materially from the estimates made or implied
in such forward-looking statements and, accordingly, reliance should not be
placed on such statements.


The terms 'ReNeuron' or 'the Company' refer to ReNeuron Group plc and its
subsidiary undertakings.



                      This information is provided by RNS
            The company news service from the London Stock Exchange